» Articles » PMID: 28232800

Circulating ECV-Associated MiRNAs As Potential Clinical Biomarkers in Early Stage HBV and HCV Induced Liver Fibrosis

Overview
Journal Front Pharmacol
Date 2017 Feb 25
PMID 28232800
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic hepatitis B (HBV) and C (HCV) virus infection is associated with the activation of hepatic stellate cells (HSCs) toward a myofibroblastic phenotype, resulting in excessive deposition of extracellular matrix, the development of liver fibrosis, and its progression toward cirrhosis. The gold standard for the detection and staging of liver fibrosis remains the liver biopsy, which is, however, associated with some mild and severe drawbacks. Other non-invasive techniques evade these drawbacks, but lack inter-stage specificity and are unable to detect early stages of fibrosis. We investigated whether circulating vesicle-associated miRNAs can be used in the diagnosis and staging of liver fibrosis in HBV and HCV patients. : Plasma samples were obtained from 14 healthy individuals and 39 early stage fibrotic patients (F0-F2) with chronic HBV or HCV infection who underwent transient elastography (Fibroscan). Extracellular vesicles were extracted from the plasma and the level of miRNA-122, -150, -192, -21, -200b, and -92a was analyzed by qRT-PCR in total plasma and circulating vesicles. Finally, these same miRNAs were also quantified in vesicles extracted from activating primary HSCs. : In total plasma samples, only miRNA-200b (HBV: = 0.0384; HCV: = 0.0069) and miRNA-122 (HBV: 0.0001; HCV: = 0.0007) were significantly up-regulated during early fibrosis. In circulating vesicles, miRNA-192 (HBV: 0.0001; HCV: 0.0001), -200b (HBV: 0.0001; HCV: 0.0001), -92a (HBV: 0.0001; HCV: 0.0001), and -150 (HBV: = 0.0016; HCV: = 0.004) displayed a significant down-regulation in both HBV and HCV patients. MiRNA expression profiles in vesicles isolated from activating primary mouse HSCs resembled the miRNA expression profile in circulating vesicles. : Our analysis revealed a distinct miRNA expression pattern in total plasma and its circulating vesicles. The expression profile of miRNAs in circulating vesicles of fibrotic patients suggests the potential use of these vesicle-associated miRNAs as markers for early stages of liver fibrosis.

Citing Articles

The interactive role of microRNA and other non-coding RNA in hepatitis B (HBV) associated fibrogenesis.

Sartorius K, Wang Y, Sartorius B, Antwi S, Li X, Chuturgoon A Funct Integr Genomics. 2025; 25(1):24.

PMID: 39847120 DOI: 10.1007/s10142-024-01519-4.


Extracellular Vesicles in Viral Liver Diseases.

Kouroumalis E, Tsomidis I, Voumvouraki A Viruses. 2024; 16(11).

PMID: 39599900 PMC: 11598962. DOI: 10.3390/v16111785.


Biomarkers in Detection of Hepatitis C Virus Infection.

Woo J, Choi Y Pathogens. 2024; 13(4).

PMID: 38668286 PMC: 11054098. DOI: 10.3390/pathogens13040331.


Extracellular Vesicles as Delivery Vehicles for Non-Coding RNAs: Potential Biomarkers for Chronic Liver Diseases.

Ferro A, Saccu G, Mattivi S, Gaido A, Herrera Sanchez M, Haque S Biomolecules. 2024; 14(3).

PMID: 38540698 PMC: 10967855. DOI: 10.3390/biom14030277.


Plasma Pattern of Extracellular Vesicles Isolated from Hepatitis C Virus Patients and Their Effects on Human Vascular Endothelial Cells.

Grossini E, Smirne C, Venkatesan S, Tonello S, DOnghia D, Minisini R Int J Mol Sci. 2023; 24(12).

PMID: 37373343 PMC: 10299492. DOI: 10.3390/ijms241210197.


References
1.
Verlinden W, Bourgeois S, De Maeyer M, Vonghia L, Vanwolleghem T, Michielsen P . Validation of APRI and FIB-4 score in an Antwerp cohort of chronic hepatitis C patients. Acta Gastroenterol Belg. 2015; 78(4):373-80. View

2.
Yoshioka Y, Konishi Y, Kosaka N, Katsuda T, Kato T, Ochiya T . Comparative marker analysis of extracellular vesicles in different human cancer types. J Extracell Vesicles. 2013; 2. PMC: 3760642. DOI: 10.3402/jev.v2i0.20424. View

3.
Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bail B, Adhoute X . Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut. 2005; 55(3):403-8. PMC: 1856085. DOI: 10.1136/gut.2005.069153. View

4.
Thampanitchawong P, Piratvisuth T . Liver biopsy:complications and risk factors. World J Gastroenterol. 2002; 5(4):301-304. PMC: 4695539. DOI: 10.3748/wjg.v5.i4.301. View

5.
Reeves H, Friedman S . Activation of hepatic stellate cells--a key issue in liver fibrosis. Front Biosci. 2002; 7:d808-26. DOI: 10.2741/reeves. View